Spoštovani kupci!
Zaradi prenove spletne strani in prehoda na OJS spletna prodaja trenutno ne dela. Prosim, če sporočite, kaj bi radi kupili, na prodaja@medrazgl.si. Dopišite vaše ime in priimek, naslov ter način plačila (s predračunom, ob povzetju ali z gotovino, če prezvamete gradivo v živo v prostorih uredištva v času uradnih ur).
Hvala za razumevanje!
MENU
Anatomy
Anesthesiology
Biochemistry
Biomedical Informatics
Biophysics
Cell Biology
Clinical Cases
Dentistry
Dermatovenerology
Emergency Medicine
Family Medicine
Forensic Medicine
Gynecology and Obstetrics
Histology and Embryology
History of Medicine
Human Genetics
Hygiene
Infectious Diseases
Internal Medicine
Medical Deontology and Philosophy
Medical Psychology
Microbiology and Immunology
Neurology
Occupational Medicine
Oncology
Ophthalmology
Orthopaedics
Otorhinolaryngology
Pathology
Pathophysiology
Pediatrics
Pharmacology and Experimental Toxicology
Physical and Rehabilitation Medicine
Physiology
Psychiatry
Radiology
Social Medicine
Surgery
Toxicology
Research papers
Clinical research paper
Preclinical research paper
Sponsored articles

Archive » 2015 » 3 »

Harm Reduction Programs for People Who Use Psychoactive Substances

Nonsuicidal Self-Injury in Adolescents

Psychopathology: Disorders of Perception

The Use of Ketamine Therapy in Treatment-Resistant Depression

From the Individual to the Family: Understanding and Applicability of Medical Family Therapy in Somatic Medicine

Dementia in People with Intellectual Disability

Neurobiological Meaning of Autoanamnestic Data from a Patient with Alcohol Addiction

Cognitive Impairment after Ischemic Stroke

Paranoid and Catatonic Schizophrenia – Case Report

Neuroleptic Malignant Syndrome and a Case Report

Is the Use of Cognitive Modulators Reasonable in Treatment of Bipolar Mood Disorder?

Principles of Pain Sensation, Perception and Recognition

Bipolar Disorder

Therapeutic Interventions in Geriatric Population with Mental Health Disorders

Post-authorization Safety and Efficacy Study of Olanzapine (Zolrix®) in the Treatment of Schizophrenia and Bipolar Mania

Post-Authorization Safety and Efficacy Study of Escitalopram (Ecytara®) in the Treatment of Depression and Anxiety Disorders

© 2024 Društvo Medicinski razgledi | Na vrh strani / To top ↑